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Persistent activation of interlinked 
type 2 airway epithelial gene 
networks in sputum-derived cells 
from aeroallergen-sensitized 
symptomatic asthmatics
Anya C. Jones1,2, Niamh M. Troy1,2, Elisha White1, Elysia M. Hollams1, Alexander M. Gout1,  
Kak-Ming Ling1, Anthony Kicic  1,2,3,4, Stephen M. Stick1,2,3,4, Peter D. Sly  5, Patrick G. Holt1,5, 
Graham L. Hall1,6,7 & Anthony Bosco1
Atopic asthma is a persistent disease characterized by intermittent wheeze and progressive loss of 
lung function. The disease is thought to be driven primarily by chronic aeroallergen-induced type 
2-associated inflammation. However, the vast majority of atopics do not develop asthma despite 
ongoing aeroallergen exposure, suggesting additional mechanisms operate in conjunction with type 
2 immunity to drive asthma pathogenesis. We employed RNA-Seq profiling of sputum-derived cells 
to identify gene networks operative at baseline in house dust mite-sensitized (HDMS) subjects with/
without wheezing history that are characteristic of the ongoing asthmatic state. The expression of 
type 2 effectors (IL-5, IL-13) was equivalent in both cohorts of subjects. However, in HDMS-wheezers 
they were associated with upregulation of two coexpression modules comprising multiple type 2- and 
epithelial-associated genes. The first module was interlinked by the hubs EGFR, ERBB2, CDH1 and 
IL-13. The second module was associated with CDHR3 and mucociliary clearance genes. Our findings 
provide new insight into the molecular mechanisms operative at baseline in the airway mucosa in 
atopic asthmatics undergoing natural aeroallergen exposure, and suggest that susceptibility to asthma 
amongst these subjects involves complex interactions between type 2- and epithelial-associated gene 
networks, which are not operative in equivalently sensitized/exposed atopic non-asthmatics.
Asthma is a chronic disease of the conducting airways that is characterized by episodic airways inflammation, 
airways remodeling, and progressive loss of lung function. It is increasingly recognized as a highly heterogeneous 
disorder comprising multiple sub-phenotypes1. The atopic form of the disease develops in early childhood, and 
is initiated by sensitization to inhalant allergens exemplified by house dust mite (HDM). One of the important 
drivers of progression of atopic asthma towards chronicity is thought to be repeated cycles of airways inflamma-
tion, in particular severe exacerbations triggered by respiratory infections which involve interactions between 
host anti-viral and atopy-associated effector mechanisms2,3, and the rate of the ensuing decline in lung function 
is related to the frequency and intensity of these exacerbations4–6. There is also evidence to suggest that air-
way remodeling can proceed independent of these inflammatory processes7 but addressing these pathways was 
beyond the scope of this investigation.
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Recent clinical intervention studies, including those demonstrating that treatment with anti-IgE reduces 
exacerbation frequency, confirms the causal role of type 2 responses in these intermittent events8–10, and these 
findings have provided the impetus for the present study. In particular, the degree to which chronic exposure 
to type 2-stimulatory perennial aeroallergens contributes to the inflammatory milieu in the airway mucosa of 
sensitized atopics during the periods between overt exacerbation events, thus potentially influencing long-term 
persistence of the asthma-associated wheezy phenotype, remains unclear, and this question was the focus of this 
investigation. Resolving this issue is important in relation to design of future therapeutic strategies for prevention 
of asthma progression i.e. is it sufficient to target severe exacerbation events alone, or is it potentially necessary to 
also dampen ongoing aeroallergen-driven type 2 reactivity at baseline in sensitized/perennially exposed subjects?
We have addressed this issue in a study population consisting of 22 yr olds from an unselected birth cohort 
resident in Perth, Western Australia11. We have previously shown that the dominant asthma-associated aeroaller-
gen in this region is HDM12 which is present in local households at high levels throughout the year13, and accord-
ingly the study focused primarily on atopics who were sensitized and chronically exposed to HDM. Our approach 
was based on the recent demonstration that induced sputum, which contains a sample of cell populations present 
on the airway surface, can potentially be used for gene expression profiling of wheeze-associated inflammatory 
responses in asthmatics14,15.
We hypothesized that the presence versus absence of current wheezing history amongst HDMS subjects will 
be reflected by variations in gene network patterns amongst cell populations accessible at the airway epithelial 
surface. To test this hypothesis, we have employed RNA-Seq in conjunction with coexpression network analysis 
to profile asthma-associated gene networks in sputum samples collected at (symptom-free) baseline from study 
groups matched for age, HDM sensitization status and environmental exposure, but dichotomous with respect 
to wheezing symptom expression. Our findings suggest that upregulation of type 2 signature genes exemplified 
by the effector cytokines IL-5 and IL-13 is a common feature across the whole HDMS/exposed population at 
baseline, but in the subgroup with history of current wheeze the type 2 signature is more complex, and is uniquely 
networked with a series of concomitantly upregulated epithelial cell associated pathways.
Results
Demographics of the study population. The study was based on case/control comparisons of HDMS or 
nonatopic subjects with or without a history of wheeze (Table 1). A total of 68 high quality (cell viability >48%; 
squamous cell contamination <32%; RNA integrity number > 6) sputum samples were available for transcrip-
tome analysis (Supplementary Fig. S1). The characteristics of the 4 study groups are illustrated in Table 1. There 
was no difference in age, gender, height, or weight between the four groups. Except for cat, the prevalence of pos-
itive skin prick tests to common allergens was not different between HDMS wheezers and HDMS nonwheezers. 
Asthma medication use was significantly higher in the HDMS wheezers for inhaled short-acting beta-agonists 
(p < 0.001) and combination therapy (p = 0.004) (Supplementary Table S1).
Cellular composition of the sputum. The cellular composition of sputum from these subjects was dom-
inated by macrophages and neutrophils, which constituted 88–94% of the overall population, and the propor-
tion of these cell types (and overall total yields) did not differ between the groups (Supplementary Table S2). 
Squamous cells and lymphocytes comprised on average 4.5% and 1.8% respectively and did not differ between 
groups. Small numbers of eosinophils were detectable only in the atopic groups and were highest in the wheezers 
(Supplementary Table S2).
Differential gene expression in HDMS nonwheezers. Gene expression patterns in sputum were firstly 
compared between HDMS nonwheezers and nonatopic controls. The data showed that 80 genes were upregulated 
(including the type 2 signature genes IL-5 [4.15 logfold] and IL-13 [2.92 logfold]) and 11 genes were down-
regulated (FDR < 0.05, Supplementary Table S3). To obtain detailed information on the regulatory interactions 
between these genes, we utilized experimentally supported findings from published studies (prior knowledge) to 
reconstruct the underlying network16. It is noteworthy that this analysis includes relationships such as binding 
interactions between proteins, and regulatory interactions between transcription factors and their target genes. 
This analysis showed that the genes were mainly involved in IL-1B and IL-5/IL-13 signaling (Fig. 1).
Differential gene expression in HDMS wheezers. Next we compared gene expression patterns between 
HDMS wheezers and nonatopic controls. The data showed that 842 genes were upregulated (again including IL-5 
[5.29 logfold], IL-13 [3.03 logfold] and IL-33 [2.59 logfold]) and 11 genes were downregulated in the wheezers 
(FDR < 0.05, Supplementary Table S4). As illustrated in Fig. 2, reconstruction of the prior knowledge network 
revealed that these genes revolved around a few hubs - erb-b2 receptor tyrosine kinase 2 (ERBB2/HER2), which 
was involved in 59 interactions (also known as ‘edges’ in graph theory17), IL-13 (44 edges), and E-Cadherin/
CDH1 (37 edges).
Further, we compared gene expression patterns between HDMS wheezers versus HDMS nonwheezers. The 
data showed that 859 genes were upregulated and 8 genes were downregulated (FDR < 0.05, Supplementary 
Table S5). The prior knowledge network constructed from these genes (Fig. 3) unveiled epidermal growth factor 
receptor (EGFR, 60 edges), ERBB2 (56 edges) and CDH1 (38 edges) as hub genes. It is noteworthy that IL-13 did 
not feature here since it was not differentially expressed after adjustment for multiple testing (p-value = 0.028, 
FDR = 0.27). In contrast, IL-33 was upregulated in this comparison (2.74 logfold; Supplementary Table S5).
Finally, we compared gene expression in nonatopic wheezers with nonatopic controls, and a single gene - LIM 
domain binding 3 (LDB3), was upregulated in the subjects with wheeze (FDR = 2.6 × 10−5). Given the lack of 
differentially expressed genes and the small sample size these data were not considered further.
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Network analysis identifies asthma-associated modules operating at baseline in HDMS 
wheezers. It has been reported that hub genes in biological interaction networks often exhibit limited expres-
sion changes in experimental asthma models18, thus a potential caveat of the above analyses, which focused on 
Nonatopic Nonatopic HDMS HDMS
Pcontrols wheezers nonwheezers wheezers
Number of participants 21 7 24 16
Male (%) 42.9 42.9 54.2 56.3 0.804
Wheeze in past 12 months [A] (%) 0.0 100.0 0.0 100.0
Doctor diagnosis of asthma ever [B] (%) 9.5 a 57.1 b,c 41.7 a,c 93.8 b <0.001
Asthma medication use in past 12 months 
[C] (%) 4.8 a 14.3 a 8.3 a 75.0 b <0.001
Current medicated asthma [Postive for 
A,B&C] (%) 0.0 14.3 0.0 75.0 0.007^
Current asthma [Positive for A&B] (%) 0.0 57.1 0.0 93.8 0.033^
Airways hyperresponsiveness (%) 0.0 0.0 0.0 43.7 <0.001
Parental history of asthma at recruitment 
(%) 10.0* 28.6 21.7* 37.5 0.263
Current rhinoconjunctivitis (%) 0.0 a 42.9 b 0.0 a 75.0 b <0.001
Current smokers (%) 23.8 14.3 33.3 25.0 0.740
Height (m) 1.76 [1.65–1.79] 1.70 [1.59–1.78] 1.76 [1.66–1.82] 1.73 [1.60–1.84] 0.415
Weight (kg) 67.6 [61.5–82.9] 76.9 [56.0–83.0] 75.1 [66.4–89.7] 70.3 [60.9–102.4] 0.561
Hip to waist ratio 0.83 [0.79–0.88] 0.83 [0.78–0.85] 0.85 [0.81–0.90] 0.87 [0.77–0.88] 0.754
Age at assessment and sputum collection 
(years) 22.0 [21.8–22.2] 21.9 [21.6–21.9] 22.2 [21.6–22.5] 22.0 [21.6–22.5] 0.660
Prevalence of positive skin prick tests (%)
 Any positive 0.0 0.0 100.0 100.0 1.000^^
 HDM 0.0 0.0 100.0 100.0 1.000^^
 Egg white 0.0 0.0 4.2 12.5 0.327^^
 Mold 0.0 0.0 16.7 25.0 0.519^^
 Grass mix 0.0 0.0 45.8 50.0 0.796^^
 Cow’s milk 0.0 0.0 0.0 6.3 0.215^^
 Grass pollen 0.0 0.0 50.0 50.0 1.000^^
 Dog 0.0 0.0 20.8 31.3 0.456^^
 Cockroach 0.0 0.0 29.2 50.0 0.182^^
 Fungus 0.0 0.0 12.5 18.8 0.588^^
 Cat 0.0 0.0 33.3 75.0 0.0106^^
HDM SPT wheal diameter (mm):
 Sum of D. pteronyssinus and D. farinae 0.0 [0.0–0.0] 0.0 [0.0–0.0] 10.3 [6.0–17.3] 15.9 [10.0–20.2] 0.062^^
 Participants with IgE data (n): 19 7 23 14
 HDM-IgE ≥ 0.35 kU/L (%) 5.3 a 14.3 a,b 69.6 b,c 100 c <0.001
Baseline lung function measures from all participants:
 FEV1 4.0 [3.4–4.5] 3.6 [3.2–4.9] 4.2 [3.4–4.6] 3.5 [2.9–5.0] 0.809
 FEV1% of predicted 100.1 [88.6–102.9] 104.3 [97.7–105.1] 96.1 [89.1–106.5] 93.2 [85.5–102.6] 0.445
 FEV1 (z score) 0.0 [−1–0.3] 0.4 [−0.2–0.4] −0.3 [−0.9–0.6] −0.6 [−1.2–0.2] 0.445
 FVC 4.7 [3.7–5.7] 4.2 [3.8–5.8] 5.1 [4.3–5.9] 4.6 [3.7–6.4] 0.767
 FVC % of predicted 96.6 [94.5–106.2] 104.0 [96.3–111.6] 100.5 [95.9–109.6] 100.9 [89.0–105.9] 0.596
 FVC (z score) −0.3 [−0.5–0.5] 0.3 [−0.3–1.0] 0.0 [−0.4–0.8] 0.1 [−0.9–0.5] 0.627
 FEV1/FVC 0.85 [0.80 −.0.89] 0.88 [0.79–0.91] 0.84 [0.77–0.87] 0.79 [0.76–0.84] 0.136
 FEV1/FVC % of predicted 0.87 [0.85–0.88] 0.87 [0.85–0.88] 0.86 [0.85–0.87] 0.86 [0.85–0.88] 0.608
 Forced exhaled nitric oxide, ppb 25.5 [19.5–30.0] a 24.0 [17.9–39.1] a 31.5 [22.2–58.2] a 47.2 [35.1–88.7] b 0.004
Table 1. Characteristics of the study population. Median [interquartile range] is displayed for all continuous 
measures. P value is derived from analyses comparing the four groups: prevalence values were compared by Chi 
square analysis; continuous measures were compared by Kruskal Wallis analysis. Where significant differences 
were observed between the four group groups (P < 0.05 in table), each letter denotes sputum groups that do 
not differ significantly at the 0.05 level after adjusting for multiple pair-wise comparisons (e.g. a vs a = not 
significantly different, a vs b = significantly different). *Data was missing for 1 participant in each group. 
^Wheezing groups only were compared by Mann Whitney U test. ^^Atopic groups only were compared by 
Chi square (IgE binary variables) or Mann Whitney U test (SPT wheal diameter). Skin prick test were classified 
positive if wheal diameter was ≥3 mm. Baseline spirometry data are reported in absolute terms, in addition to z 
score and predicted terms that were calculated using the 2012 Global Lung Function Initiative equations72.
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differentially expressed genes, is that some hubs may have escaped detection. These hubs can be captured using 
coexpression network analysis. Moreover, network analysis additionally provides a deeper understanding of 
the molecular context in which differentially expressed genes operate. Hence, we constructed a genome-wide 
coexpression network, utilizing the data from both HDMS groups (n = 40). The resulting network comprised 
14,833 genes organized into 23 coexpression modules. To identify disease-associated modules, we plotted the 
−log10 p-values derived from the above differential expression analyses on a module-by-module basis. The data 
showed that the modules were not different between HDMS nonwheezers and nonatopic controls (Supplementary 
Fig. S4A). In contrast, three modules (designated A, P, and Q) were upregulated in HDMS wheezers versus the 
other two groups (nonatopic controls, HDMS nonwheezers, Supplementary Fig. S4B,C).
Module reconstruction reveals hub genes in HDMS wheezers. Module “P” contained 319 genes, 
and based on prior knowledge the dominant hubs in the network were EGFR (35 edges) and CDH1 (31 edges, 
Supplementary Fig. S5). Module “Q” contained 440 genes, and the hubs in the reconstructed prior knowledge 
network were ERBB2 (35 edges) and IL-13 (27 edges, Supplementary Fig. S6). Principal component analysis 
showed that these two modules (P, Q) were highly correlated (Pearson correlation: 0.897, p-value = 4.441 × 10−15) 
(Supplementary Fig. S7), suggesting they are subunits of a larger parent module. Therefore, we merged them into 
a single network. In the merged network the dominant hubs were EGFR (73 edges), ERBB2 (65 edges), CDH1 (56 
edges) and IL-13 (48 edges, Supplementary Fig. S8). Notably, these hubs connect to both common and unique 
pathways (Fig. 4). The biological function of the genes that interact with the hubs was interrogated using Gene 
Ontology terms (Supplementary Table S6) and Pubmed searches (Supplementary Table S7). Module “A” con-
tained 506 genes. It was not possible to reconstruct this module using prior knowledge, because no interactions 
were found for the vast majority of genes. Therefore we used unbiased correlation patterns to reconstruct the 
network19. This analysis showed that the highest-ranking coexpression hubs were TEKT1, FOXJ1, ARMC3, PIFO, 
DNAH5, RSPH1, FAM81B, SNTN, ERICH3, DNAH9, and CAPSL (Fig. 5). Of note, CDHR3, which is a known 
susceptibility gene for asthma exacerbations and a receptor for rhinovirus species C20,21, was a highly ranked 
coexpression hub (rank 19 out of 506 genes) within module “A”.
Network module enrichment analysis reveals enrichment for airway epithelial cells. The molec-
ular signatures database22 was employed to interrogate the modules for enrichment of gene ontology terms and 
immunological signatures in the data (Supplementary Table S8). This analysis showed that the CDHR3-associated 
module (module A) was enriched with genes expressed in ciliated epithelial cells, whereas the other modules 
contained signatures related to mesenchymal and epithelial cells (cell junction, tissue development, epithe-
lial development). We also employed the Human Gene Atlas to interrogate the data, and module P was most 
strongly associated with bronchial epithelial cells (p-value = 8 × 10−9), and module Q was associated with trachea 
(p-value = 0.006). Signatures related to T cells, mast cells, and neutrophils were also detected, but these were not 
highly ranked (data not shown).
Adjustment of differential expression for potential confounders. Next we determined if the 
associations between the modules and wheeze amongst HDMS subjects were potentially confounded by varia-
tions in cellular composition, smoking, or the use of medications. We counted the proportion of epithelial cells 
in the two HDMS groups, and the mean proportion was 1.2% (±1.6 SD), and this was not different between 
wheezers and nonwheezers (p-value = 0.7). We repeated the analyses adjusting for variations in the propor-
tion of squamous cells, and the data were unchanged (Supplementary Fig. S9B). We adjusted the analysis for 
Figure 1. Differential gene network comparing HDMS nonwheezers versus nonatopic controls. Differentially 
expressed genes were identified with an edgeR analysis. Gene expression patterns in sputum were compared 
between HDMS nonwheezers and nonatopic controls. The wiring diagram of the underlying gene network was 
reconstructed employing prior knowledge from the literature (Ingenuity Knowledge Base). Genes highlighted 
in red denote upregulation, whilst green indicates downregulation in HDMS nonwheezers.
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proportions of eosinophils, and this reduced the number of differentially expressed genes and associated modules 
(Supplementary Fig. S9C). We adjusted the analysis for smoking, and the data were unchanged (Supplementary 
Fig. S9D). Finally, to investigate the impact of medications on the data, we employed Upstream Regulator 
Analysis23 to systematically search for steroid-related activation signatures, and no significant signatures were 
identified (data not shown).
Replication of the CDHR3-associated mucociliary module “A” in two independent asthmatic 
datasets. We then wanted to determine if the modules could be replicated in independent data sets. We 
downloaded two data sets from the gene expression omnibus repository. The first data set was from asth-
matic bronchial epithelial brushings (GSE76226), and the second data set was from asthmatic sputum samples 
(GSE41863). Coexpression analysis of both data sets demonstrated that firstly the CDHR3-associated module 
(module A) was reproducible (Supplementary Fig. S10), and secondly that CDHR3 was a highly ranked coex-
pression hub (rank 12 out of 1750 genes, GSE76226; rank 12 out of 271 genes, GSE41863) in both independent 
data sets. Further, we found that the highest-ranking genes in our dataset that were detected in the independent 
data sets were amongst the top 15% of coexpression genes in the validation datasets (data not shown). It was not 
possible to validate the other modules, because the bulk of the microarray probe sets did not pass our stringent 
filtering criteria (see supplementary methods).
CDHR3 and EGFR expression is higher in atopic asthmatic bronchial epithelial cells versus 
nonatopic controls. We finally wanted to validate the expression of selected hubs at the protein-level in 
Figure 2. Differential gene network comparing HDMS wheezers versus nonatopic controls. Differentially 
expressed genes were identified with an edgeR analysis. Gene expression patterns in sputum were compared 
between HDMS wheezers and nonatopic controls. The wiring diagram of the underlying gene network was 
reconstructed using prior knowledge from the literature (Ingenuity Knowledge Base). Genes highlighted in red 
denote upregulation, whilst molecules in green indicate downregulation in HDMS wheezers.
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an independent cohort of subjects. CDHR3 was selected for these studies because it is a candidate susceptibility 
gene for asthma exacerbations, but its normal endogenous cellular function is unknown. We also selected EGFR 
and ERBB2 for validation because these were the dominant hubs in the other modules. These studies focused on 
Figure 3. Differential gene network comparing HDMS wheezers versus HDMS nonwheezers. Differentially 
expressed genes were identified with an edgeR analysis. Gene expression patterns in sputum were compared 
between HDMS wheezers versus HDMS nonwheezers. The wiring diagram of the underlying gene network was 
reconstructed employing prior knowledge from the literature (Ingenuity Knowledge Base). Genes highlighted 
in red denote upregulation, whilst molecules in green indicate downregulation in HDMS wheezers.
Figure 4. Common and unique genes networked with the 4 hub genes: EGFR, ERBB2, CDH1 and IL-13. Venn diagram 
illustrating common and unique genes that are networked with each hub gene in merged modules “P” and “Q”.
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bronchial epithelial cells, based on bioinformatics analyses of molecular signatures in the data (Supplementary 
Table S8). The staining was carried out on samples from HDM sensitized children with asthma and from non-
atopic controls. The demographics of the paediatric cohort are presented in Supplementary Table S11. The data 
for CDHR3 showed there was positive staining localized to the apical surface of columnar epithelial cells in both 
cohorts (Fig. 6a, Supplementary Fig. S11), and this was more intense and defined in airway epithelial cells derived 
from the asthmatic children (Fig. 6b). EGFR expression was also increased in the atopic asthmatics (Fig. 6a,b, 
Supplementary Fig. S12). In contrast, mean expression of ERBB2 (in red) was 3-fold higher in the atopic asthmat-
ics; however, this was not statistically significant because it was only elevated in a subset of the subjects (Fig. 6a,b, 
Supplementary Fig. S13).
Discussion
Asthma is acknowledged to be a heterogeneous disease with multiple different phenotypes1. Local inflammation 
and tissue remodeling in the airways are common features of ongoing disease7, and there is evidence suggesting 
that these processes can act independently and/or in concert to drive asthma pathogenesis7. The specific focus of 
this study is asthma in young adult atopics who are highly sensitized to HDM allergen. In this regard, an increas-
ing body of epidemiological and experimental evidence (reviewed2,3,24), now supported by a range of intervention 
studies4–6, argues for a causal role for type 2-associated inflammatory mechanisms in the aetiology and pathogen-
esis of atopic asthma. However, the precise molecular details of the underlying causal pathways remain incom-
pletely understood. In particular, the relative contributions of airways inflammation resulting from acute severe 
exacerbation events versus chronic exposure to relevant aeroallergens to time-related lung function decline in 
asthmatics, remains unknown. Moreover, while it is undisputed that sensitization to perennial aeroallergens is an 
important asthma risk factor, community wide studies clearly demonstrate that only a minority of sensitized sub-
jects including of those highly sensitized to HDM25 ever develop persistent wheeze. This suggests that additional 
cofactor(s) may be required to unmask the full pathogenic potential of aeroallergen-specific sensitization. A 
likely candidate in this regard is the airway epithelium, which may function as both a target for type 2-associated 
inflammation and/or as an active participant via production of a range of immunomodulatory molecules that can 
regulate the local functioning of Th2 cells and group 2 innate lymphoid cells8–10,26,27.
Our current study design represents an unbiased approach towards testing this possibility. In the core exper-
iments we have sampled induced sputum cell populations from equivalently sensitized adult atopics undergoing 
natural aeroallergen exposure, and employed gene expression profiling and ensuing bioinformatics analyses to 
compare and contrast gene network patterns after stratification on the basis of wheezing phenotypes. Our find-
ings provide novel insight into the nature of the molecular processes ongoing on the airway mucosal surface at 
the time of sampling.
Our initial analyses showed that a type 2 gene expression program was upregulated in baseline sputum sam-
ples from HDM sensitized atopics, regardless of whether these subjects have current history of wheeze. This 
is consistent with earlier immunohistochemical findings indicating that mast cell degranulation in the airway 
mucosa is present in both atopic asthmatics and atopic nonasthmatics, albeit to differing degrees28. Of note, 
although asthma medication use was significantly higher in the HDMS wheezers, steroid-related signatures were 
absent in the transcriptome, likely reflecting the participants abstaining from using their medication 72 hours 
prior to respiratory assessment and sputum collection, as requested by the study protocol. In the present study, 
Figure 5. Differential gene network comparing HDMS wheezers versus nonatopic controls/HDMS 
nonwheezers. Gene co-expression network analysis (WGCNA) was employed to construct the gene networks 
and unbiased correlation patterns were utilized to reconstruct the underlying wiring diagram of the mucociliary 
clearance module “A”. CDHR3 is identified as a hub and dominant hubs are highlighted in red.
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the key type 2 effectors IL-5 and IL-13 were upregulated to comparable degrees in both groups, however in 
HDMS nonwheezers the overall type 2 program was restricted to a few IL-5/IL-13-associated genes. In con-
trast, hundreds of genes were upregulated in HDMS wheezers, and network analysis suggested that these genes 
function in the context of two discrete coexpression modules. Reconstruction of the first module unveiled the 
hub genes EGFR, ERBB2, CDH1, and IL-13, which dominated the network structure. The second coexpression 
module comprised genes that control mucociliary clearance, and CDHR3 was identified as a coexpression hub 
within this module. Overall, our findings suggest that the molecular mechanisms that determine susceptibility 
to asthma-associated wheeze amongst HDM sensitized atopics involve complex interactions between type 2 and 
epithelial gene networks. Whilst interactions between type 2 and epithelial cells have previously been implicated 
in the pathogenesis of atopic asthma26,27, our study provides a holistic view of the underlying molecular networks 
operating in the context of natural allergen exposure.
EGFR is a complex signaling pathway that can be activated by multiple ligands (e.g. amphiregulin, EGF, 
epiregulin, HB-EGF, TGF-a)29. Puddicombe et al. reported that EGFR was upregulated in the bronchial epithe-
lium of patients with asthma and in particular severe asthma in comparison to healthy controls, and expression 
levels were correlated with sub-epithelial reticular membrane thickening30. Le Cras et al. reported that inhibition 
of EGFR signaling with a tyrosine kinase inhibitor reduced goblet cell hyperplasia, airway hyperreactivity and 
airway smooth muscle thickening in a chronic mouse model of HDM exposure31. The latter two phenotypes were 
also reduced by conditional transgenic expression of a dominant negative EGFR mutant in the lung epithelium. 
Together, these data suggest that upregulation of EGFR signaling in the context of HDM exposure plays a causal 
role in the development of asthma-related traits.
ERBB2 is an orphan receptor from the EGFR family. It lacks a ligand-binding domain and transduces signals 
by forming heterodimers with other ligand bound members of the EGF receptor family, including EGFR. Polosa 
et al. reported that ERBB2 expression was not different in bronchial epithelial cells from asthmatic subjects com-
pared to healthy controls32. Song and Lee identified ERBB2 as an asthma susceptibility gene based on a pathways 
analysis of genome-wide single nucleotide polymorphism data33. Modena et al. studied coexpression networks in 
bronchial epithelial brushings from severe asthmatics and showed that ERBB2 was a major hub34,35. To date, the 
function of ERBB2 in asthma has not been investigated. Vermeer et al. reported that blockade of ERBB2 signaling 
in differentiated airway epithelial cells cultured at air-liquid interface reduced the number of ciliated epithelial 
cells36. Kettle et al. reported that blocking ERBB2 signaling in vitro attenuated neuregulin-induced upregulation 
of MUC5AC and MUC5B37. Notably, our network analysis showed that ERBB2 connects to anterior gradient 2 
Figure 6. Increased expression of CDHR3 and EGFR in bronchial epithelial cells from HDM sensitized 
asthmatics versus nonatopic controls. The expression of the hub genes CDHR3, EGFR and ERBB2 was validated 
at the protein-level in an independent cohort. Bronchial epithelial cells were obtained from HDM sentitized 
atopics with asthma and nonatopic controls. (a) Bronchial epithelial cells were immunofluorescently stained for 
CDHR3 expression23, EGFR expression71, ERBB2 expression71 and nuclei with DAPI (blue). Staining images 
were then overlaid over bright field images taken of the same field of view. Note: mag 200×; inset 400×. (b) 
Quantification of the images demonstrated that the expression of CDHR3 and EGFR was more intense in the 
atopics with asthma. The expression of ERBB2 was not different between the groups. Mann-Whitney U Test was 
utilized to test for statistical significance. ***p-value < 0.001, **p-value < 0.01.
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(AGR2) and ERBB2 has been shown to upregulate the transcription and secretion of AGR238,39. AGR2 binds to 
immature MUC5AC in the endoplasmic reticulum, where it is thought to play a role in mucin folding. AGR2 defi-
cient mice have profound defects in intestinal mucus production and reduced mucus production in the airways 
of allergen challenged mice40,41. It has also been shown that deficiency in the ERBB2 adapter protein ERBB2IP 
(also known as ERBB2 interacting protein or ERBIN), leads to deregulation of TGFB1 signaling, and this in turn 
is associated with type 2 activation42. In summary, upregulation of ERRB2 networks may influence asthma patho-
genesis by modulating epithelial differentiation, mucus production and/or type 2 signaling.
E-cadherin (CDH1) is a cell adhesion molecule that forms adherence junctions between adjacent airway epi-
thelial cells and maintains epithelial barrier integrity43. HDM disrupts epithelial barrier function by delocalizing 
E-cadherin and other junction molecules, and this is thought to enhance allergic sensitization and inflamma-
tion44. Polymorphisms in CDH1 are associated with airways remodeling and lung function decline, but only in 
those asthma patients using corticosteroids45. Dysregulation of CDH1 networks may impact on barrier function, 
inflammation, and airways remodeling.
IL-13 plays a central role in the pathogenesis of asthma by driving mucus production, airways 
hyper-responsiveness, and airways remodeling24. It is produced by Th2 and group 2 innate lymphoid cells (ILC2), 
and it can also be produced by macrophages46,47. IL-13 itself was not differentially expressed in HDMS wheezers 
versus nonwheezers, however network analysis demonstrated that in wheezers it was connected to an extensive 
set of genes that have established roles in mouse models of allergic asthma. For instance, IL-33 stimulates the pro-
duction of IL-5 and IL-13 by type 2 innate lymphoid cells and type 2 cells48,49, and in the presence of GM-CSF it 
can drive allergic inflammation at sub-threshold allergen doses50. In animal models, deficiency of multiple genes 
from the IL-13 network can impact on asthma-related traits, including allergic sensitization and/or inflammation 
(ALOX1551, CYBB52), and airways hyperresponsiveness and mucus production/goblet cell hyperplasia (POSTN53, 
SERPINB3/454). Moreover, transgenic expression of SPDEF or FOXA3 leads to upregulation of pulmonary type 2 
cytokines and increased goblet cell differentiation, eosinophilic inflammation, and airway hyperresponsiveness55. 
It is noteworthy, that whilst both IL-13 and EGFR ligands can induce the transcription of mucin genes, microar-
ray profiling studies have shown that these pathways have largely independent effects on gene regulation in bron-
chial epithelial cells, and they play distinct roles in goblet cell metaplasia40,56,57. Many other pathways were also 
identified that are regulated by IL-13 and relevant to asthma pathogenesis (e.g. CCL17, CCL26, CTGF, FCER1A, 
KITLG, MUC2, NOS2, TLR3, Supplementary Table S6).
The CDHR3-associated coexpression module comprised genes expressed in ciliated epithelial cells that con-
trol mucociliary clearance. The primary function of cilia is to beat in a synchronous manner to clear mucus from 
the airways and into the pharynx. Thomas et al. reported that cilia beat frequency was decreased in patients with 
asthma, and severe asthmatics had abnormal ciliary orientation and microtubule defects58. Notably, employing 
network analysis we showed that CDHR3 was a highly ranked coexpression hub within this module. Further, 
Griggs et al. recently demonstrated that CDHR3 is exclusively expressed on ciliated airway epithelial cells and not 
on other epithelial cells (e.g. goblet and basal cells) consistent with our network analysis showing that CDHR3 
is associated with ciliated epithelial cells59. Bonnelykke et al. reported that polymorphisms in CDHR3 were 
associated with recurrent, severe childhood asthma exacerbations20. Bochkov et al. showed that CDHR3 is the 
receptor for Rhinovirus-C21. Of note, CDHR3 was selected for these validation studies, because although it is 
a susceptibility gene for severe asthma exacerbations and a receptor for Rhinovirus-C, its endogenous cellular 
role is unknown. The other genes in this module have well-established roles in the function of cilia. For example, 
FOXJ1 is a transcription factor, which is essential for the formation of motile cilia; PIFO controls cilia retraction; 
and dyneins (e.g. DNAH5, DNAH9) are the motor proteins that mediate ciliary beating. We examined CDHR3 
protein expression in bronchial epithelial cells, and we demonstrated that expression was localized to the api-
cal surface of columnar epithelial cells and was increased in HDM sensitized atopics with asthma compared to 
nonatopic controls. Ross et al. reported that CDHR3 was highly upregulated during mucociliary differentiation 
of human airway epithelial cells60. Detailed mechanistic studies will be required to dissect the role of CDHR3 in 
ciliated epithelial cells.
The findings above highlight candidate pathways underlying airways inflammation and airway remodeling 
in the pathogenesis of asthma/wheeze, and our computational analysis which combines data-driven coexpres-
sion analysis together with mechanistic data from prior studies to infer network structure suggests that under 
baseline conditions during ongoing aeroallergen exposure, these pathways are intertwined and work in concert. 
Moreover, asthma is a highly heterogeneous disease, and the contribution of type 2 inflammation versus airways 
remodeling is likely to be highly variable from subject to subject7,61. Our study also represents a single snapshot in 
time, and thus the stability of these phenotypes on repeated sampling is unknown. In particular, superimposition 
of respiratory infection upon this background of persistent aeroallergen exposure, which is known to precipitate 
acute exacerbations and to accelerate lung function decline in asthmatics62, may markedly alter the interactions 
between and/or the relative contributions of these pathways to the overall process. Follow-up studies in larger 
populations will be required to further elucidate these issues.
This exploratory study has limitations that should be acknowledged. The molecular profiling studies were 
based on a heterogeneous cell population, and the pathways we identified were mainly associated with airway 
epithelial cells, which represent a minority population in sputum. The proportion of epithelial cells in the sputum 
samples did not differ between the HDMS subjects with or without wheeze, but it was not possible to differen-
tiate between ciliated and non-ciliated epithelial cells. Future studies employing single cell RNA-Seq profiling 
will provide more detailed information on the role of individual cell types in this phenotype. The differentially 
expressed genes we identified were related to proportions of eosinophils, but this was not surprising given that 
eosinophils were increased in HDMS wheezers and are known to correlate with type 2-associated inflammation61. 
We observed asymmetry in the number of up and downregulated genes in our analyses. Previous studies suggest 
this may occur when RUV adjustment is employed to remove the effect of unwanted variation in the data, but this 
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adjustment was necessary to obtain a uniform p-value distribution63. Prior knowledge was employed to recon-
struct the gene networks, which relies on data derived from experimental settings that may be far removed from 
the current study, and this is oversimplified given that genes can function in a context specific manner. Follow-up 
mechanistic studies will therefore be required to elucidate the specific cellular and molecular mechanisms 
involved. Additionally, hyperosmotic stress effects on epithelial cells resulting from mannitol treatment may have 
influenced the gene expression profiles detected, but this is unlikely to explain the main differences between those 
with/without wheeze as the treatment was standardized between the groups. Notwithstanding these caveats, our 
findings are consistent with the general hypothesis that progression from subclinical responsiveness to aeroal-
lergen exposure in atopic asthmatics to expression of the persistent wheezing phenotype involves the establish-
ment of coexpression networks linking type 2 effector pathways in immune cells recruited to the airway surface 
with genes expressed in adjacent epithelial cells that have been implicated in myriad asthma-relevant functions, 
including mucosal barrier integrity, mucus production, tissue remodeling, responsiveness to irritants, and (exem-
plified by IL-33) intensification of aeroallergen-specific type 2 immunity. Targeting drug development programs 
specifically at these chronic mechanisms, as opposed to simply those that are triggered during acute exacerbation 
events, may provide improved therapeutics for prevention of asthma progression in atopics who represent the 
segment of the population at greatest risk of this disease.
Methods
Study population. This study was conducted within the 22-year follow-up of an unselected longitudinal 
birth cohort recruited in Perth, Western Australia, namely the Western Australia Pregnancy Cohort (Raine study, 
refs11,25). The 22-year follow-up included 1234 active participants. All aspects of the study were approved by 
the University of Western Australia Human Ethics Committee (ethics number: RA/4/1/5202), carried out in 
accordance with the University guidelines and regulations, and participants provided written informed consent. 
Subjects were selected for case/control studies based on their clinical characteristics and the availability of high 
quality sputum samples (see below). Participants were classed as having current wheeze if they indicated in the 
22-year follow-up questionnaire that they had wheezed in the past 12 months. Current asthma was defined as a 
positive doctor diagnosis of asthma ever, in addition to both wheeze and asthma medication use in the past 12 
months12. Atopy was defined by skin prick test wheal ≥3 mm for the common allergens as outlined in the online 
supplement. Four clinical groups were defined; (i) HDM sensitized atopics (SPT ≥ 3.0 mm) with current wheeze 
during previous 12mths, with or without a physician diagnosis of “asthma ever” (HDMS wheezers, n = 16); (ii) 
HDM sensitized atopics without current asthma or wheeze (HDMS nonwheezers, n = 24); (iii) nonatopics with 
current asthma and/or wheeze (nonatopic wheezers, n = 7); (iv) nonatopics without current asthma or wheeze 
(nonatopic controls, n = 21).
Sputum induction and processing. Participants were required to cease mediation use for a period of 72 h 
prior to respiratory assessment and sputum collection. Induced sputum was obtained after mannitol inhalation 
challenge64. The samples were stored at 4 °C for up to 2 hours prior to processing. Sputum was processed (see the 
online data supplement) by selection and subsequent disruption of mucus plugs with forceps to minimize con-
tamination with saliva65.
Transcriptome profiling by RNA-Seq. Total RNA was extracted from good quality sputum (cell viabil-
ity > 48%; squamous cell contamination <32%; RNA integrity number >6) employing TRIzol (Ambion) fol-
lowed by RNeasy MinElute (QIAgen). The mean ± sd RNA integrity number was 7.6 ± 1.0 as assessed on the 
bioanalzyer (Agilent). RNA samples were shipped on dry ice to the Australian Genome Research Facility for 
library preparation (TruSeq Stranded mRNA Library Prep Kit, Illumina) and sequencing (Illumina HiSeq. 2500, 
50-bp single-end reads, v4 chemistry). The raw data are available at the NCBI Short Read Archive (accession; 
SRP057350).
RNA-Seq data analysis. The quality of the RNA-Seq data was assessed with the Bioconductor package Rqc 
(Supplementary Fig. S2). Reads were aligned to the reference genome (hg19) using Subread, and summarized 
at the gene-level using featureCounts66. Genes with less than 300 total counts were removed from the analysis. 
Differentially expressed genes were identified employing Empirical analysis of digital gene expression data in R 
(EdgeR) with Benjamini-Hochberg False Discovery Rate (FDR) control for multiple testing67. The analysis was 
adjusted using the Remove Unwanted Variation (RUV) algorithm68 to minimize the potential for biological and/
or technical variation to impact on the analysis (Fig. S3). All factor levels were analysed in a single model, with or 
without adjustment for unwanted variation and additional covariates.
A coexpression network was constructed employing the weighted gene coexpression network analysis 
(WGCNA) algorithm16. Prior to network analysis, the count data was transformed using the variance stabiliz-
ing transformation algorithm67. Modules associated with clinical traits were identified by plotting the −log10 
p-values from the edgeR analysis on a module-by-module basis. The wiring diagram of selected gene networks 
was reconstructed employing two different methods. The first method utilized “prior knowledge” comprising 
experimentally supported molecular relationships based on data from the Ingenuity Systems KnowledgeBase 
(www.ingenuity.com)16. The second method utilized unbiased connectivity patterns derived from WGCNA, and 
the network was visualized using VisANT19. Biological pathways and functions enriched in the data were identi-
fied with MSigDb and Enrichr22,69. Upstream regulator analysis was performed using Ingenuity systems software, 
and the threshold for statistical significance was p-value < 0.01 and absolute activation Z-score > 2.023.
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Immunostaining. Primary bronchial epithelial cells were obtained from 13 healthy nonatopic children and 
12 atopic asthmatic children with HDM allergy who were undergoing elective surgery for non-respiratory related 
conditions. Samples were obtained under a separate study that was approved by the Princess Margaret Hospital 
for Children’s Human Ethics Committee (937EP), and all methods were performed in accordance with the rele-
vant guidelines and regulations. Written consent was obtained from each participant’s legal guardian after being 
fully informed about the nature and purpose of the study. Cytospins were prepared and stained for CDHR3, 
EGFR, ERBB2 and DAPI using methods previously described (see online supplementary methods).
Preprint Server. This work has been posted as a preprint on the bioRxiv server70.
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